Research into a protein for treatment of cancer brings prestigious awardtext editorEmerging Infectious Diseases
12]. In many cases, the application of cancer treatment is what drives loss of the ligand binding site or point mutations which prevent binding [13,14,15,16,17,18,19]. These are expected outcomes for oncoproteins
frequently associated with the oncogenic conversion of two specific protein kinases, RET and BRAF. Small-molecule inhibitors of both kinases have already reached the clinical testing stage. Protein kinases other than RET and BRAF are also being evaluated for their potential in thyroid-cancer treatment...
Xiang, W. et al. Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer.J. Med. Chem.64, 13487–13509 (2021). ArticleCASPubMedPubMed CentralGoogle Scholar Snyder, L. B. et al. The discovery o...
“For the first time, our research has shown that without RAC1B, breast cancer stem cells can’t form tumours and become more vulnerable to chemotherapy, making the treatment even more effective. Positively RAC1B isn’t needed for healthy cells so targeting RAC1B...
However, due to the lack of tumor specificity, they kill both cancer cells and normal cells, eliciting severely toxic side effects1. Hence, ideal agents for cancer treatment are those can selectively kill cancer cells without harming normal cells. So TRAIL is a promising candidate for cancer ...
Also in two patient-derived lung cancer xenograft models, Lu7336 and Lu7187, RG7787 showed anti-tumor efficacy. In monotherapy two treatment cycles were moderately efficacious in the Lu7336 model but showed good anti-tumor activity in the KRAS mutant Lu7187 model (26% and 80% tumor growth ...
Targeting protein acetylation for breast cancer treatment The inhibitors targeting protein acetylation can be classified into three categories, namely, KAT, KDAC, and bromodomain protein (acetyl-lysine readers) inhibitors (Additional file1: Table S2). KAT inhibitors suppress the activity of acetyltransferas...
In this manner, the selective inhibition of the altered PMT can provide a basis for therapeutic intervention with a reasonable therapeutic index, owing to the unique dependence of the genetically-defined cancer on PMT activity. Early reports of small-molecule inhibitors of PMTs presented either non-...
Protein E7(43-62) 是一种具有抗肿瘤作用的 E7 衍生肽 (即在 E7 蛋白中跨越 43 到 62 个氨基酸残基的短肽)。 Protein E7(43-62)Chemical Structure CAS No. :143853-58-1 *Please selectQuantitybefore adding items. 所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务...